Skip to main content
Niagen Bioscience, Inc. logo

Niagen Bioscience, Inc. — Investor Relations & Filings

Ticker · NAGE ISIN · US1710774076 LEI · 529900OPI7B8JPXCVS70 US Manufacturing
Open in API
Filings indexed 954 across all filing types
Latest filing 2010-09-17 Regulatory Filings
Country US United States of America
Listing US NAGE

About Niagen Bioscience, Inc.

https://www.niagenbioscience.com/

Niagen Bioscience, Inc. (formerly ChromaDex) is a bioscience company focused on the science of nicotinamide adenine dinucleotide (NAD+). The company aims to improve healthspan and support healthy aging by developing products that restore and optimize cellular NAD+ levels. Its core proprietary ingredient is Niagen®, a patented and clinically studied form of nicotinamide riboside (NR), a precursor to NAD+. Niagen® is the key component in the company's consumer dietary supplement brand, Tru Niagen®, and is also developed for the food, beverage, and pharmaceutical markets. The company's research is supported by numerous human clinical studies, a portfolio of over 50 owned and licensed patents, and collaborations with global research institutions.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2010
Regulatory Filings
2010-09-17 English
Regulatory Filings 2010
Regulatory Filings Classification · 95% confidence The document is a letter from ChromaDex Corporation to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-1. This is a regulatory filing related to securities registration and does not contain financial statements or detailed financial data. The document is short (2021 characters) and is an official communication about the registration process, not a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement.
2010-09-15 English
AMENDMENT NO. 1 TO FORM S-1
Capital/Financing Update Classification · 95% confidence The document is titled 'Amendment No. 1 to Form S-1' and is a registration statement filed with the SEC under the Securities Act of 1933. It includes detailed information about the offering of common stock by selling stockholders, including the number of shares, pricing, plan of distribution, risk factors, management discussion and analysis, executive compensation, and financial statements. Form S-1 is a registration statement used for initial public offerings or other securities offerings and is not a financial report like an annual or quarterly report. This document is a capital markets filing related to fundraising and securities registration, which aligns with the category 'Capital/Financing Update (CAP)'. The document is substantive and not merely an announcement or certification, so it is not classified as RPA or RNS. Therefore, the appropriate classification is CAP with high confidence.
2010-09-15 English
Regulatory Filings 2010
Regulatory Filings
2010-08-31 English
FORM S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes detailed information about the offering, selling stockholders, risk factors, business description, management discussion and analysis, executive compensation, and financial statements. This type of filing is related to capital raising activities and securities registration, not an annual report, earnings release, or other types of filings. Therefore, it fits the category of Capital/Financing Update filings.
2010-08-18 English
FORM 10-Q
Interim / Quarterly Report Q2 2010
2010-08-17 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.